BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26206899)

  • 41. Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
    Arnes M; Hvingel B; Orbo A
    Anticancer Res; 2014 May; 34(5):2319-24. PubMed ID: 24778038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
    De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
    Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to comment on: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.
    Kim MK; Seong SJ
    J Gynecol Oncol; 2020 Sep; 31(5):e89. PubMed ID: 32808507
    [No Abstract]   [Full Text] [Related]  

  • 44. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Letter to editor in response to: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.
    Sabour S; Shokrgozar M
    J Gynecol Oncol; 2020 Sep; 31(5):e88. PubMed ID: 32808506
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison the Diagnostic Value of Dilatation and Curettage Versus Endometrial Biopsy by Pipelle--a Clinical Trial.
    Sanam M; Majid MM
    Asian Pac J Cancer Prev; 2015; 16(12):4971-5. PubMed ID: 26163624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
    Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
    Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
    Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
    Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
    Sletten ET; Arnes M; Vereide AB; Ørbo A
    Anticancer Res; 2018 May; 38(5):2883-2889. PubMed ID: 29715112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
    Orbo A; Arnes M; Pettersen I; Larsen K; Hanssen K; Moe B
    Acta Obstet Gynecol Scand; 2010 Nov; 89(11):1438-46. PubMed ID: 20955098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women.
    Ravi RD; Kalra J; Srinivasan R; Bagga R; Jain V; Suri V; Sachdeva N
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):983-989. PubMed ID: 33773565
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
    Zhou H; Cao D; Yang J; Shen K; Lang J
    Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
    Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
    Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review.
    Peng H; Jiang J; Li X
    Reprod Sci; 2022 Nov; 29(11):3278-3284. PubMed ID: 35641856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB; Kaino T; Sager G; Ørbo A;
    Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study.
    Xu Z; Yang B; Shan W; Liao J; Shao W; Wu P; Zhou S; Ning C; Luo X; Zhu Q; Zhang H; Ma F; Guan J; Chen X
    Gynecol Oncol; 2023 Jul; 174():133-141. PubMed ID: 37182434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system.
    Ercan CM; Duru NK; Sakinci M; Alanbay I; Karasahin KE; Baser I
    Gynecol Endocrinol; 2010 Feb; 26(2):125-8. PubMed ID: 20074021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
    Wildemeersch D; Janssens D; Weyers S
    Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia].
    Weng M; Li L; Feng S; Xie M; Hong S
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1350-4. PubMed ID: 22985581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.